CurrentBlue Cross Blue Shield - MassachusettsPolicy 184

Axillary reverse mapping / reverse lymphatic mapping for breast cancer

This policy addresses use of axillary reverse mapping (ARM) or reverse lymphatic mapping performed during sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) to prevent lymphedema in individuals treated for breast cancer and applies to BCBS Massachusetts commercial and Medicare products.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyAxillary reverse mapping / reverse lymphatic mapping for breast cancer

Policy CodePolicy 184

Change TypeNo material change

Effective Date

Next Review Date

Key ActionObtain precertification/preauthorization when the procedure is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

InvestigationalCoverage stance

Not coveredOutpatient stance

Precert required (IP)Authorization

~38%ARM ID rate (SLNB)

OR 0.20

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Investigational — ARM for SLNB and ALND

SLNB and ALND investigational statements: Axillary reverse mapping/reverse lymphatic mapping performed during sentinel lymph node biopsy to prevent lymphedema in individuals who are being treated for breast cancer is considered INVESTIGATIONAL. Axillary reverse mapping/reverse lymphatic mapping performed during axillary lymph node dissection to prevent lymphedema in individuals who are being treated for breast cancer is considered INVESTIGATIONAL.

For outpatient settings, axillary reverse mapping (ARM) performed during sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) is explicitly stated as not a covered service for the following product lines when performed outpatient: Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM. Providers should confirm member-specific benefits and any preauthorization requirements for inpatient procedures as described elsewhere in the policy.

The policy bibliography lists multiple prospective studies, randomized trials, systematic reviews, and professional guidance that evaluate ARM but do not themselves establish coverage policy. Representative citations include Han et al., 2016 (systematic review and meta-analysis of prospective studies), multiple feasibility and prospective reports (e.g., Boneti et al. 2009; Casabona et al. 2009; Connor et al. 2013), controlled trials and meta-analyses (e.g., Yuan et al. 2019; Guo et al. 2021), and the American Society of Breast Surgeons concise overview (2022). These references are provided for clinical context and evidence review.

The listed reference entries are literature citations only and do not include any not medically necessary determinations. The policy’s not medically necessary determinations are addressed separately; these bibliography entries serve to document the evidence base considered during policy development.

Coding

CPT CodesCPT

No codes listed

Provider Actions & Authorization

Prior Authorization

Inpatient Precertification Required

For services described in this policy, precertification/preauthorization is REQUIRED for all products when the procedure is performed inpatient. Providers must obtain authorization prior to scheduling inpatient procedures to avoid claim denials or delays.

Precertification required for all inpatient procedures

Note

Outpatient Noncoverage

For outpatient services described in this policy, these services are not covered for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO Blue SM, and Medicare PPO Blue SM. Check product-specific benefit documents for exceptions or prior authorization requirements where applicable.

Commercial Managed Care (HMO and POS), Outpatient = Not a covered service
Commercial PPO and Indemnity, Outpatient = Not a covered service
Medicare HMO Blue SM, Outpatient = Not a covered service

Background

Lymphedema is an accumulation of interstitial fluid resulting from disruption of normal lymphatic drainage. It may be primary (congenital) or secondary (acquired), with breast cancer treatment — including lymphadenectomy, axillary dissection, and regional radiotherapy — being among the most common causes of secondary lymphedema. Risk of breast cancer–related lymphedema increases with greater numbers of nodes removed, regional radiation, obesity, and postoperative wound infection; some studies report higher risk in Black breast cancer survivors. Axillary reverse mapping (ARM) is a surgical technique that uses subcutaneous injection of blue dye, fluorescence (indocyanine green), or radioisotope to identify lymphatic channels and nodes draining the arm during SLNB or ALND with the intent of distinguishing and potentially preserving arm-draining lymphatics to reduce the risk of postoperative lymphedema.

Definitions

inv-15: Axillary reverse mapping (ARM) — technique description and purpose

TechniqueSubcutaneous administration of blue dye, fluorescence (indocyanine green), or radioisotopes to visualize lymphatic drainage pathways of the arm and breast.

PurposeDistinguish arm-draining versus breast-draining lymphatics to enable identification and potential preservation of axillary lymph nodes and lymphatics during SLNB and/or ALND.

RationaleBecause the axilla and breast have mostly separate drainage pathways, preserving lymphatics identified by ARM may reduce risk of lymphedema by avoiding removal of nodes that drain only the arm.

inv-16: Lymphedema — definition and types

DefinitionAn accumulation of fluid due to disruption of lymphatic drainage; most often caused by acquired damage to the lymphatic system (secondary lymphedema), though can be primary (congenital).

Primary vs Secondary